Image: Lindsay Picture A
Image: Lindsay Picture A

IDENTIFYING THE
BENLYSTA PATIENT

IDENTIFYING
THE
BENLYSTA
PATIENT

BENLYSTA can be
used in patients
with lupus who
are
experiencing
active disease.

WHO IS YOUR BENLYSTA
PATIENT?

Watch these patients* discuss their
experience with lupus and BENLYSTA.

Image: Lindsay Picture B

MEET LINDSAY*

A patient with lupus

LEARN MORE

Image: Valerie Picture B

MEET VALERIE*

A patient with lupus and
organ
damage

LEARN MORE

Image: Sophia Picture A

MEET SOPHIA*

A pediatric patient with
lupus

LEARN MORE

* Hypothetical patient profiles. May not be representative of all BENLYSTA patients.

Image: Lindsay Picture B

 

LINDSAY*

A patient diagnosed with lupus
3 years ago

  • 37 years old
  • Diagnosed with lupus 3 years ago

Current medications

  • Hydroxychloroquine
    300 mg/day – 3 years
  • Prednisone 7.5 mg/day –
    8 months
    • Decreased to: 5 mg/day
      (2 years)
    • Increased to: 15 mg/day
      (the last 4 months)

Lab values and physical exam

  • Positive antinuclear antibodies (ANA) (1:160)
  • ESR 30 mm/hr
  • Anti-dsDNA elevated
  • Swelling in joints of hands, knees, and ankles

anti-dsDNA = anti-double-stranded DNA;
ESR = erythrocyte sedimentation rate.

Discover what BENLYSTA can do for a patient like Lindsay

SEE THE DATA

SEE LINDSAY’S DIAGNOSIS STORY
REVIEW LINDSAY’S
INITIAL TREATMENT
LEARN ABOUT LINDSAY’S BENLYSTA TREATMENT
Image: Valerie Picture B

 

VALERIE*

A patient diagnosed with lupus
7 years ago
experiencing organ damage

  • 30 years old
  • Diagnosed with lupus 7 years ago

Current medications

  • Hydroxychloroquine 400 mg/day
    – 2 years
  • MMF (not tolerated)
  • Prednisone 10 mg/day

Lab values and physical exam

  • Scarring alopecia (SDI score = 1)
  • Osteoporosis
  • Arthritis
  • Anti-dsDNA elevated

In an SLE clinical trial in Black patients, efficacy response rates were higher with BENLYSTA vs placebo. The improvement was not statistically significant and the safety profile of BENLYSTA was consistent with the overall population.

anti-dsDNA = anti-double-stranded DNA;
MMF = mycophenolate mofetil; SDI = SLICC/
ACR Damage Index.

See how BENLYSTA could help your patients like Valerie

SEE HOW

SEE VALERIE’S DIAGNOSIS STORY
REVIEW VALERIE’S
INITIAL TREATMENT
LEARN ABOUT VALERIE’S BENLYSTA TREATMENT
Image: Sophia Picture A

 

SOPHIA*

A pediatric patient diagnosed with lupus 2 years ago

  • 12 years old
  • Diagnosed with lupus 2 years ago

Current medications

  • Hydroxychloroquine 200 mg/day
    – 2 years
  • Prednisone 7.5 mg/day – 2 years

Current lab values

  • Positive antinuclear antibodies (ANA)
    (1:80)
  • Proteinuria ≥0.5 mg/24 hours
  • Low complement C3/C4

Disease activity score

  • SELENA-SLEDAI = 12

SELENA-SLEDAI = Safety of Estrogens in
Lupus Erythematosus: National Assessment
version of the Systemic Lupus Erythematosus Disease Activity Index.

Do you know a patient like Sophia? Learn how to get
them started on BENLYSTA.

START NOW

SEE SOPHIA’S DIAGNOSIS STORY
REVIEW SOPHIA’S
INITIAL TREATMENT
LEARN ABOUT SOPHIA'S BENLYSTA TREATMENT

Choose
BENLYSTA now
for your patients
like Lindsay,
Valerie, and
Sophia

Image: Sophia Picture B
Image: Sophia Picture B